ADC

78개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved78 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Lymphoma+3
Trials 10Status Active
ADCLimited DatastaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin-Blmf)

Multiple Myeloma; Neoplasms · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#antibody-drug-conjugate#Neoplasms+1
Trials 9Status Recruiting
ADCLimited DatastaleCelldex TherapeuticsPhase 2

glembatumumab vedotin (glembatumumab vedotin)

Advanced Malignant Solid Neoplasm; Estrogen Receptor Negative · Melanoma

#Melanoma#ADC#Phase2#antibody-drug-conjugate#AdvancedMalignantSolidNeoplasm+2
Trials 9Status Active
ADCLimited DatastaleAbbViePhase 3

Depatuxizumab mafodotin (Depatuxizumab mafodotin)

Glioblastoma · Glioblastoma

#Glioblastoma#ADC#Phase3#antibody-drug-conjugate#AbbVie
Trials 8Status Active
ADCLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

[vic-]trastuzumab duocarmazine (SYD985, SYD985 ([vic-]trastuzumab duocarmazine))

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 7Status Recruiting
ADCLimited DatastaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin lyophilized powder)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#antibody-drug-conjugate#GSK
Trials 6Status Active
ADCLimited DatastaleAstraZenecaPhase 3

Sonesitatug vedotin (Sonesitatug vedotin)

Stomach Neoplasms · Gastric Cancer

#GastricCancer#ADC#Phase3#antibody-drug-conjugate#StomachNeoplasms+2
Trials 6Status Recruiting
ADCLimited DatastaleSeagen Inc.Phase 2

cBR96-Doxorubicin Immunoconjugate (SGN-15, SGN-15 (cBR96-Doxorubicin Immunoconjugate))

Prostatic Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase2#antibody-drug-conjugate#ProstaticNeoplasms+1
Trials 5Status Active
ADCLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab emtansine [Kadcyla])

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 5Status Active
ADCLimited DatastaleSeagen Inc.Phase 2

ladiratuzumab vedotin (ladiratuzumab vedotin)

Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#SmallCellLungCancer+3
Trials 5Status Active
ADCLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Patritumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 4Status Recruiting
ADCLimited DatastaleSeagen Inc.Phase 2

denintuzumab mafodotin (denintuzumab mafodotin)

Lymphoma, B-cell; Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-cell

#LymphomaB-cell#ADC#Phase2#antibody-drug-conjugate#Lymphoma+2
Trials 4Status Discontinued
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin, anti-PD-1 antibody.)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#IneligibleOrRefusedTransplantPat+1
Trials 3Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

Patritumab (Patritumab)

Head and Neck Neoplasms · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#ADC#Phase2#antibody-drug-conjugate#HeadandNeckNeoplasms+1
Trials 2Status Active
ADCLimited DatastaleGenentech, Inc.Phase 2

Pinatuzumab Vedotin (Pinatuzumab Vedotin)

Follicular Lymphoma; Diffuse Large B-Cell Lymphoma · Follicular Lymphoma

#FollicularLymphoma#ADC#Phase2#antibody-drug-conjugate#DiffuseLargeB-CellLymphoma+1
Trials 2Status Active
ADCLimited DatastaleThe Netherlands Cancer InstitutePhase 2

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR

#EGFR#ADC#Phase2#antibody-drug-conjugate#Non-SmallCellLungCarcinoma+2
Trials 1Status Recruiting
ADCLimited DatastaleCentral South UniversityPreclinical

Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate (Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate)

Sepsis (SMQ); Opportunistic Infections · Sepsis (SMQ)

#SepsisSMQ#ADC#Preclinical#antibody-drug-conjugate#OpportunisticInfections+1
Trials 1Status Active
ADCLimited DatastaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages)

AL Amyloidosis; Amyloidosis · AL Amyloidosis

#ALAmyloidosis#ADC#Phase2#antibody-drug-conjugate#Amyloidosis+1
Trials 1Status Recruiting
ADCLimited DatastaleAmgenPhase 2

Blinatumomab and Inotuzumab Ozogamicin (Blinatumomab and Inotuzumab Ozogamicin)

Acute Lymphoblastic Leukemia; Immunotherapy · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#ADC#Phase2#antibody-drug-conjugate#Immunotherapy+1
Trials 1Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#IneligibleOrRefusedTransplantPat+1
Trials 1Status Recruiting

3 / 4 pages

← PreviousNext →